News

The U.S. Food and Drug Administration (FDA) no longer considers available clinical data sufficient to move forward with an application seeking approval of uniQure’s AMT-130 for Huntington’s disease, the company said. The company had planned to submit a biologics license application (BLA) early next year, based on…

Researchers in China have developed a new system to grow the specific type of brain cells that are lost in Huntington’s disease, and have seen benefits in testing it in a mouse model of the neurodegenerative disorder. Transplanting these cells into the brains of the animal model lessened the…

Three years of treatment with Ingrezza (valbenazine) led to rapid and sustained reductions in the severity of uncontrolled movements known as chorea for people with Huntington’s disease. That’s according to data from a long-term Phase 3 clinical trial called KINECT-HD2 (NCT04400331). Participants completing the three years of…

Up to two years of pridopidine treatment continues to slow Huntington’s disease progression among patients not taking certain standard treatments called antidopaminergic medications (ADMs). That’s according to a new analysis comparing long-term outcomes from pridopidine-treated people with Huntington’s in the Phase 3 PROOF-HD clinical trial (NCT04556656) against…

Available evidence does not indicate that treatments approved for people with Alzheimer’s disease can improve cognitive function in people with Huntington’s disease, according to a review study. “The existing literature does not provide sufficient evidence to support the use of cholinesterase inhibitors or memantine for managing cognitive symptoms in…

The Hereditary Disease Foundation (HDF), committed to advancing research on Huntington’s disease (HD) and potential treatments, has changed its name to Huntington’s Disease Foundation. “This name change is more than symbolic — it is a powerful reaffirmation of our purpose,” Meghan Donaldson, Huntington’s Disease Foundation CEO, said in…

uniQure’s experimental gene therapy AMT-130 safely and effectively slows the progression of Huntington’s disease, according to top-line, three-year data from two Phase 1/2 clinical trials. At 36 months, the use of high-dose AMT-130 was shown to slow Huntington’s progression by 75% — results the developer called “statistically significant”…

Three months of daily treatment with Skyhawk Therapeutics’ oral candidate SKY-0515 safely and effectively reduced blood levels of Huntington’s disease-associated proteins in people with the neurodegenerative condition. That’s according to interim results from a substudy of a Phase 1 clinical trial that specifically showed a greater reduction with…

Healthtech company Neuralight is teaming up with the CHDI Foundation to explore the possibility of monitoring eye movements as a method to track Huntington’s disease activity in clinical trials. The CHDI Foundation is a nonprofit biomedical research organization dedicated to advancing new therapies that can slow the…

Pridopidine may safely and effectively slow Huntington’s disease progression in patients who aren’t taking antidopaminergic medications, which are commonly used for psychiatric symptoms and chorea, or involuntary movements. That’s according to full results from the Phase 3 PROOF-HD clinical trial  (NCT04556656), which tested pridopidine against a…